Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Dec 20;2014(12):CD010404.
doi: 10.1002/14651858.CD010404.pub2.

Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection

Tim J Benstead  1 , Colin H Chalk, Natalie E Parks
Affiliations
Meta-Analysis

Treatment for cryoglobulinemic and non-cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection

Tim J Benstead et al. Cochrane Database Syst Rev. .

Abstract

Background: Peripheral neuropathy is the most common neurologic complication of hepatitis C virus (HCV) infection. The pathophysiology of the neuropathy associated with HCV is not definitively known; however, proposed mechanisms include cryoglobulin deposition in the vasa nervorum and HCV-mediated vasculitis. The optimal treatment for HCV-related peripheral neuropathy has not been established.

Objectives: To assess the effects of interventions (including interferon alfa, interferon alfa plus ribavirin, corticosteroids, cyclophosphamide, plasma exchange, and rituximab) for cryoglobulinemic or non-cryoglobulinemic peripheral neuropathy associated with HCV infection.

Search methods: On 26 August 2014, we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, and EMBASE. We also searched two trials registers, the Networked Digital Library of Theses and Dissertations (NDLTD) (October 2014), and three other databases. We checked references in identified trials and requested information from trial authors to identify any additional published or unpublished data.

Selection criteria: We included all randomized controlled trials (RCTs) and quasi-RCTs involving participants with cryoglobulinemic or non-cryoglobulinemic peripheral neuropathy associated with HCV infection. We considered any intervention (including interferon alfa, interferon alfa plus ribavirin, corticosteroids, cyclophosphamide, plasma exchange, and rituximab) alone or in combination versus placebo or another intervention ('head-to-head' comparison study design) evaluated after a minimum interval to follow-up of at least six months.

Data collection and analysis: We used standard methodological procedures expected by The Cochrane Collaboration. The planned primary outcome was change in sensory impairment (using any validated sensory neuropathy scale or quantitative sensory testing) at the end of the follow-up period. Other planned outcomes were: change in impairment (any validated combined sensory and motor neuropathy scale), change in disability (any validated disability scale), electrodiagnostic measures, number of participants with improved symptoms of neuropathy (global impression of change), and severe adverse events.

Main results: Four trials of HCV-related cryoglobulinemia fulfiled selection criteria and the review authors included three in quantitative synthesis. All studies were at high risk of bias. No trial addressed the primary outcome of change in sensory impairment. No trial addressed secondary outcomes of change in combined sensory and motor impairment, disability, or electrodiagnostic measures. A single trial of HCV-related mixed cryoglobulinemia treated with pegylated interferon alfa (peginterferon alfa), ribavirin, and rituximab versus peginterferon alfa and ribavirin did not show a significant difference in the number of participants with improvement in neuropathy at 36 months post treatment (risk ratio (RR) 4.00, 95% confidence interval (CI) 0.27 to 59.31, n = 9). One study of interferon alfa (n = 22) and two studies of rituximab (n = 61) provided adverse event data. Severe adverse events were no more common with interferon alfa (RR 7.00, 95% CI 0.38 to 128.02) or rituximab (RR 3.00, 95% CI 0.13 to 67.06) compared to the control group.

Authors' conclusions: There is a lack of RCTs and quasi-RCTs addressing the effects of interventions for peripheral neuropathy associated with HCV infection. At present, there is insufficient evidence from RCTs and quasi-RCTs to make evidence-based decisions about treatment.

PubMed Disclaimer

Conflict of interest statement

None of the review authors have any conflicts of interest to report.

Figures

1
1
Study flow diagram.
2
2
Risk of bias summary: review authors' judgements about each risk of bias item for each included study. Key: green (+) = low risk of bias; yellow (?) = unclear risk of bias; red (‐) = high risk of bias.
3
3
Forest plot of comparison: 3 Rituximab versus conventional therapy, outcome: 3.1 Severe adverse events.
1.1
1.1. Analysis
Comparison 1 Peginterferon alfa, ribavirin and rituximab versus pegyinterferon alfa and ribavirin, Outcome 1 Number improved (peripheral neuropathy).
2.1
2.1. Analysis
Comparison 2 Interferon alfa versus conventional therapy, Outcome 1 Severe adverse events.
3.1
3.1. Analysis
Comparison 3 Rituximab versus conventional therapy, Outcome 1 Severe adverse events.
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Dammacco 2010 {published data only (unpublished sought but not used)}
    1. Dammacco F, Tucci FA, Lauletta G, Gatti P, Re V, Conteduca V, et al. Pegylated interferon‐alpha, ribavirin, and rituximab combined therapy of hepatitis C virus‐related mixed cryoglobulinemia: a long‐term study. Blood 2010;116(3):343‐53. [PUBMED: 20308602] - PubMed
De Vita 2012 {published data only (unpublished sought but not used)}
    1. Vita S, Quartuccio L, Isola M, Masolini P, Sacco S, Marchi G, et al. A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome. Arthritis and Rheumatism 2010;62(Suppl 10):2201. [EMBASE: 70380187]
    1. Vita S, Quartuccio L, Isola M, Mazzaro C, Scaini P, Lenzi M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis and Rheumatism 2012;64(3):843‐53. [PUBMED: 22147661] - PubMed
Ferri 1993 {published data only (unpublished sought but not used)}
    1. Ferri C, Marzo E, Longombardo G, Lombardini F, Civita L, Vanacore R, et al. Interferon‐alpha in mixed cryoglobulinemia patients: a randomized, crossover‐controlled trial. Blood 1993;81(5):1132‐6. [PUBMED: 8382969] - PubMed
Sneller 2012 {published data only (unpublished sought but not used)}
    1. Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus‐associated cryoglobulinemic vasculitis. Arthritis and Rheumatism 2012;64(3):835‐42. [PUBMED: 22147444] - PMC - PubMed

References to studies excluded from this review

Adinolfi 1997 {published data only}
    1. Adinolfi LE, Utili R, Zampino R, Ragone E, Mormone G, Ruggiero G. Effects of long‐term course of alpha‐interferon in patients with chronic hepatitis C associated to mixed cryoglobulinaemia. European Journal of Gastroenterology & Hepatology 1997;9(11):1067‐72. [PUBMED: 9431896] - PubMed
Ammendola 2005 {published data only}
    1. Ammendola A, Sampaolo S, Ambrosone L, Ammendola E, Ciccone G, Migliaresi S, et al. Peripheral neuropathy in hepatitis‐related mixed cryoglobulinemia: electrophysiologic follow‐up study. Muscle & Nerve 2005;31(3):382‐5. [PUBMED: 15515001] - PubMed
Briani 2006 {published data only}
    1. Briani C, Chemello L, Zara G, Ermani M, Bernardinello E, Ruggero S, et al. Peripheral neurotoxicity of pegylated interferon alpha: a prospective study in patients with HCV. Neurology 2006;67(5):781‐5. [PUBMED: 16966537] - PubMed
Calleja 1999 {published data only}
    1. Calleja JL, Albillos A, Moreno‐Otero R, Rossi I, Cacho G, Domper F, et al. Sustained response to interferon‐alpha or to interferon‐alpha plus ribavirin in hepatitis C virus‐associated symptomatic mixed cryoglobulinaemia. Alimentary Pharmacology & Therapeutics 1999;13(9):1179‐86. [PUBMED: 10468699] - PubMed
Cavallo 2009 {published data only}
    1. Cavallo R, Roccatello D, Menegatti E, Naretto C, Napoli F, Baldovino S. Rituximab in cryoglobulinemic peripheral neuropathy. Journal of Neurology 2009;256(7):1076‐82. [PUBMED: 19263187] - PubMed
De Vita 2007 {published data only}
    1. Vita S, Quartuccio L, Fabris M. Rituximab in mixed cryoglobulinemia: increased experience and perspectives. Digestive and Liver Disease 2007;39(Suppl 1):S122‐8. [PUBMED: 17936213] - PubMed
Ferri 2011 {published data only}
    1. Ferri C, Cacoub P, Mazzaro C, Roccatello D, Scaini P, Sebastiani M, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmunity Reviews 2011;11(1):48‐55. [PUBMED: 21821153] - PubMed
Ghini 1996 {published data only}
    1. Ghini M, Mascia MT, Gentilini M, Mussini C. Treatment of cryoglobulinemic neuropathy with alpha‐interferon. Neurology 1996;46(2):588‐9. [PUBMED: 8614548] - PubMed
Lauta 1995 {published data only}
    1. Lauta VM, Sangro MA. Long‐term results regarding the use of recombinant interferon alpha‐2b in the treatment of II type mixed essential cryoglobulinemia. Medical Oncology (Northwood, London, England) 1995;12(4):223‐30. [PUBMED: 8832526] - PubMed
Lidove 2002 {published data only}
    1. Lidove O, Maisonobe T, Léger JM, Chauveheid MP, Cacoub P. Peripheral neuropathy and hepatitis C virus [Neuropathies périphériques et virus de l'hépatite C]. Hepato‐Gastro 2002;9(5):345‐50. [EMBASE: 2002398012]
Mazzaro 1995 {published data only}
    1. Mazzaro C, Lacchin T, Moretti M, Tulissi P, Manazzone O, Colle R, et al. Effects of two different alpha‐interferon regimens on clinical and virological findings in mixed cryoglobulinemia. Clinical and Experimental Rheumatology 1995;13(Suppl 13):S181‐5. [PUBMED: 8730503] - PubMed
Migliaresi 1995 {published data only}
    1. Migliaresi S, Tirri G. Interferon in the treatment of mixed cryoglobulinemia. Clinical and Experimental Rheumatology 1995;13(Suppl 13):S175‐80. [PUBMED: 8730502] - PubMed
Penny 1993 {published data only}
    1. Penny R. Interferon‐alpha in mixed cryoglobulinaemia patients: a randomized, crossover‐controlled trial. Interferons Cytokines 1993;24:35. [CENTRAL: CN‐00180679] - PubMed
Petrarca 2010 {published data only}
    1. Petrarca A, Rigacci L, Caini P, Colagrande S, Romagnoli P, Vizzutti F, et al. Safety and efficacy of rituximab in patients with hepatitis C virus‐related mixed cryoglobulinemia and severe liver disease. Blood 2010;116(3):335‐42. [PUBMED: 20308604] - PubMed
Saadoun 2010 {published data only}
    1. Saadoun D, Resche Rigon M, Sene D, Terrier B, Karras A, Perard L, et al. Rituximab plus peg‐interferon‐alpha/ribavirin compared with peg‐interferon‐alpha/ribavirin in hepatitis C‐related mixed cryoglobulinemia. Blood 2010;116(3):326‐34. [PUBMED: 20439619] - PubMed
Saadoun 2014 {published data only}
    1. Saadoun D, Resche Rigon M, Thibault V, Longuet M, Pol S, Blanc F, et al. Peg‐IFNα/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Annals of the Rheumatic Diseases 2014;73(5):831‐7. [PUBMED: 23606708] - PMC - PubMed
Sansonno 2003 {published data only}
    1. Sansonno D, Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti‐CD20. Blood 2003;101(10):3818‐26. [PUBMED: 12506023] - PubMed
Stefanutti 2003 {published data only}
    1. Stefanutti C, Giacomo S, Mareri M, Lorenzo F, D'Alessandri G, Angelico F, et al. Immunoadsorption apheresis (Selesorb) in the treatment of chronic hepatitis C virus‐related type 2 mixed cryoglobulinemia. Transfusion and Apheresis Science 2003;28(3):207‐14. [PUBMED: 12725944] - PubMed
Stefanutti 2009 {published data only (unpublished sought but not used)}
    1. Stefanutti C, Vivenzio A, Giacomo S, Labbadia G, Mazza F, D'Alessandri G, et al. Immunoadsorption apheresis and immunosuppressive drug therapy in the treatment of complicated HCV‐related cryoglobulinemia. Journal of Clinical Apheresis 2009;24(6):241‐6. [PUBMED: 19927363] - PubMed
Terrier 2012 {published data only}
    1. Terrier B, Krastinova E, Marie I, Launay D, Lacraz A, Belenotti P, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012;119(25):5996‐6004. [PUBMED: 22474249] - PubMed
Zaja 2003 {published data only}
    1. Zaja F, Vita S, Mazzaro C, Sacco S, Damiani D, Marchi G, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827‐34. [PUBMED: 12560225] - PubMed
Zeuzem 2010 {published data only}
    1. Zeuzem S, Nelson DR, Andreone P, Ferenci P, Herring R, Jensen DM, et al. Phase IIB study of balapiravir (RG1626; nucleoside analogue inhibitor of HCV polymerase) plus peg‐interferon alfa‐2a (40 KD) and ribavirin for CHC genotype 1: final results. Journal of Hepatology. 2010; Vol. 52:S302‐3. [EMBASE: 70131630]
Zuckerman 2000 {published data only}
    1. Zuckerman E, Keren D, Slobodin G, Rosner I, Rozenbaum M, Toubi E, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon‐alpha. Journal of Rheumatology 2000;27(9):2172‐8. [PUBMED: 10990230] - PubMed

Additional references

Acharya 2008
    1. Acharya JN, Pacheco VH. Neurologic complications of hepatitis C. The Neurologist 2008;14(3):151‐6. [PUBMED: 18469672] - PubMed
Alter 2007
    1. Alter MJ. Epidemiology of hepatitis C virus infection. World Journal of Gastroenterology 2007;13(17):2436‐41. [PUBMED: 17552026] - PMC - PubMed
Arthur 1997
    1. Arthur RR, Hassan NF, Abdallah MY, el‐Sharkawy MS, Saad MD, Hackbart BG, et al. Hepatitis C antibody prevalence in blood donors in different governorates in Egypt. Transactions of the Royal Society of Tropical Medicine and Hygiene 1997;91(3):271‐4. [PUBMED: 9231192] - PubMed
Atkins 2004
    1. Atkins D, Best D, Briss PA, Eccles M, Falck‐Ytter Y, Flottorp S, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. [PUBMED: 15205295] - PMC - PubMed
Bonetti 1997
    1. Bonetti B, Invernizzi F, Rizzuto N, Bonazzi ML, Zanusso GL, Chinaglia G, et al. T‐cell‐mediated epineurial vasculitis and humoral‐mediated microangiopathy in cryoglobulinemic neuropathy. Journal of Neuroimmunology 1997;73(1‐2):145‐54. [PUBMED: 9058770] - PubMed
Bonetti 1999
    1. Bonetti B, Scardoni M, Monaco S, Rizzuto N, Scarpa A. Hepatitis C virus infection of peripheral nerves in type II cryoglobulinaemia. Virchows Archiv : an International Journal of Pathology 1999;434(6):533‐5. [PUBMED: 10394889] - PubMed
Bril 1999
    1. Bril V. NIS‐LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. European Neurology 1999;41 Suppl 1:8‐13. [PUBMED: 10023123] - PubMed
Cacoub 2000
    1. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud‐Ratti V, et al. Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore) 2000;79(1):47‐56. [PUBMED: 10670409] - PubMed
Cacoub 2001
    1. Cacoub P, Maisonobe T, Thibault V, Gatel A, Servan J, Musset L, et al. Systemic vasculitis in patients with hepatitis C. Journal of Rheumatology 2001;28(1):109‐18. [PUBMED: 11196510] - PubMed
Cacoub 2005a
    1. Cacoub P, Saadoun D, Limal N, Léger JM, Maisonobe T. Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications. AIDS 2005;19 Suppl 3:S128‐34. [PUBMED: 16251808] - PubMed
Cacoub 2005b
    1. Cacoub P, Saadoun D, Limal N, Sene D, Lidove O, Piette JC. PEGylated interferon alfa‐2b and ribavirin treatment in patients with hepatitis C virus‐related systemic vasculitis. Arthritis and Rheumatism 2005;52(3):911‐5. [PUBMED: 15751068] - PubMed
Casato 1997
    1. Casato M, Agnello V, Pucillo LP, Knight GB, Leoni M, Vecchio S, et al. Predictors of long‐term response to high‐dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90(10):3865‐73. [PUBMED: 9354653] - PubMed
Chad 1982
    1. Chad D, Pariser K, Bradley WG, Adelman LS, Pinn VW. The pathogenesis of cryoglobulinemic neuropathy. Neurology 1982;32(7):725‐9. [PUBMED: 6283424] - PubMed
Cornblath 1999
    1. Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53(8):1660‐4. [PUBMED: 10563609] - PubMed
Cream 1974
    1. Cream JJ, Hern JE, Hughes RA, MacKenzie IC. Mixed or immune complex cryoglobulinaemia and neuropathy. Journal of Neurology, Neurosurgery, and Psychiatry 1974;37(1):82‐7. [PUBMED: 4360402] - PMC - PubMed
Cresta 1999
    1. Cresta P, Musset L, Cacoub P, Frangeul L, Vitour D, Poynard T, et al. Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus. Gut 1999;45(1):122‐8. [PUBMED: 10369715] - PMC - PubMed
Dammacco 2013
    1. Dammacco F, Sansonno D. Therapy for hepatitis c virus‐related cryoglobulinemic vasculitis. New England Journal of Medicine 2013;369(11):1035‐45. [PUBMED: 24024840] - PubMed
Egger 1997
    1. Egger M, Smith GD, Phillips AN. Meta‐analysis: principles and procedures. BMJ 1997;315(7121):1533‐7. [PUBMED: 9432252] - PMC - PubMed
El Khayat 2012
    1. Khayat HR, Fouad YM, Ahmad EA, Amin H, Ismael F, Rizk A. Hepatitis C virus (genotype 4)‐associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment. Hepatology International 2012;6(3):606‐12. [PUBMED: 22020820] - PubMed
Feldman 1994
    1. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. A practical two‐step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 1994;17(11):1281‐9. [PUBMED: 7821168] - PubMed
Ferri 1992
    1. Ferri C, Civita L, Cirafisi C, Siciliano G, Longombardo G, Bombardieri S, et al. Peripheral neuropathy in mixed cryoglobulinemia: Clinical and electrophysiologic investigations. Journal of Rheumatology 1992;19(6):889‐95. [PUBMED: 1328632] - PubMed
Global Burden of Hepatitis C Working Group 2004
    1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. Journal of Clinical Pharmacology 2004;44(1):20‐9. [PUBMED: 14681338] - PubMed
GRADEpro 2008 [Computer program]
    1. Jan Brozek, Andrew Oxman, Holger Schünemann. GRADEpro. Version 3.2 for Windows. Jan Brozek, Andrew Oxman, Holger Schünemann, 2008.
Higgins 2011
    1. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Kanda 2003
    1. Kanda T. Chronic hepatitis C infection and peripheral neuropathy; is mixed cryoglobulinemia really important?. Internal Medicine 2003;42(5):377‐8. [PUBMED: 12793703] - PubMed
Kayali 2002
    1. Kayali Z, Buckwold VE, Zimmerman B, Schmidt WN. Hepatitis C, cryoglobulinemia, and cirrhosis: A meta‐analysis. Hepatology 2002;36(4 Pt 1):978‐85. [PUBMED: 12297847] - PubMed
Lavanchy 2009
    1. Lavanchy D. The global burden of hepatitis C. Liver International 2009;29 Suppl 1:74‐81. [PUBMED: 19207969] - PubMed
Mazzaro 2011
    1. Mazzaro C, Monti G, Saccardo F, Zignego AL, Ferri C, Vita S, et al. Efficacy and safety of peginterferon alfa‐2b plus ribavirin for HCV‐positive mixed cryoglobulinemia: A multicentre open‐label study. Clinical and Experimental Rheumatology 2011;29(6):933‐41. [PUBMED: 22153224] - PubMed
Merkies 2000
    1. Merkies IS, Schmitz PI, Meché FG, Doorn PA. Psychometric evaluation of a new sensory scale in immune‐mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Neurology 2000;54(4):943‐9. [PUBMED: 10690990] - PubMed
Merkies 2002
    1. Merkies IS, Schmitz PI, Meché FG, Samijn JP, Doorn PA, Inflammatory Neuropathy Cause and Treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. Journal of Neurology, Neurosurgery, and Psychiatry 2002;72(5):596‐601. [PUBMED: 11971045] - PMC - PubMed
Nemni 1988
    1. Nemni R, Corbo M, Fazio R, Quattrini A, Comi G, Canal N. Cryoglobulinaemic neuropathy. A clinical, morphological and immunocytochemical study of 8 cases. Brain 1988;111(Pt 3):541‐52. [PUBMED: 2838123] - PubMed
Nemni 2003
    1. Nemni R, Sanvito L, Quattrini A, Santuccio G, Camerlingo M, Canal N. Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia. Journal of Neurology, Neurosurgery, and Psychiatry 2003;74(9):1267‐71. [PUBMED: 12933932] - PMC - PubMed
Pietrogrande 2011
    1. Pietrogrande M, Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus‐infected patients. Autoimmunity Reviews 2011;10(8):444‐54. [PUBMED: 21303705] - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Saadoun 2006
    1. Saadoun D, Resche‐Rigon M, Thibault V, Piette JC, Cacoub P. Antiviral therapy for hepatitis C virus‐associated mixed cryoglobulinemia vasculitis: a long‐term followup study. Arthritis and Rheumatism 2006;54(11):3696‐706. [PUBMED: 17075881] - PubMed
Saadoun 2008
    1. Saadoun D, Resche‐Rigon M, Sene D, Perard L, Karras A, Cacoub P. Rituximab combined with peg‐interferon‐ribavirin in refractory hepatitic C virus‐associated cryoglobulinaemia vasculitis. Annals of the Rheumatic Diseases 2008;67(10):1431‐6. [PUBMED: 18178690] - PubMed
Santoro 2006
    1. Santoro L, Manganelli F, Briani C, Giannini F, Benedetti L, Vitelli E, et al. HCV Peripheral Nerve Study Group. Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population. Journal of Neurology, Neurosurgery, and Psychiatry 2006;77(5):626‐9. [PUBMED: 16464900] - PMC - PubMed
Schünemann 2011
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Shihabi 2006
    1. Shihabi ZK. Cryoglobulins: an important but neglected clinical test. Annals of Clinical and Laboratory Science 2006;36(4):395‐408. [PUBMED: 17127726] - PubMed
Singleton 2008
    1. Singleton JR, Bixby B, Russell JW, Feldman EL, Peltier A, Goldstein J, et al. The Utah Early Neuropathy Scale: A sensitive clinical scale for early sensory predominant neuropathy. Journal of the Peripheral Nervous System 2008;13(3):218‐27. [PUBMED: 18844788] - PubMed
Stübgen 2009
    1. Stübgen JP. Interferon alpha and neuromuscular disorders. Journal of Neuroimmunology 2009;207(1‐2):3‐17. [PUBMED: 19171385] - PubMed
Vallat 1980
    1. Vallat JM, Desproges‐Gotteron R, Leboutet MJ, Loubet A, Gualde N, Treves R. Cryoglobulinemic neuropathy: a pathological study. Annals of Neurology 1980;8(2):179‐85. [PUBMED: 7425571] - PubMed
van Swieten 1988
    1. Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19(5):604‐7. [PUBMED: 3363593] - PubMed
Yoon 2011
    1. Yoon MS, Obermann M, Dockweiler C, Assert R, Canbay A, Haag S, et al. Sensory neuropathy in patients with cryoglobulin negative hepatitis‐C infection. Journal of Neurology 2011;258(1):80‐8. [PUBMED: 20683606] - PubMed

References to other published versions of this review

Benstead 2013
    1. Benstead TJ, Chalk CH, Parks NE. Treatment for cryoglobulinemic and non‐cryoglobulinemic peripheral neuropathy associated with hepatitis C virus infection. Cochrane Database of Systematic Reviews 2013, Issue 2. [DOI: 10.1002/14651858.CD010404] - DOI - PMC - PubMed

Publication types

MeSH terms